Abed Alqader Ibrahim, Hamdi Nsairat, Mazen Al-Sulaibi, Mohamed El-Tanani, Areej M Jaber, Zainab Lafi, Rahmeh Barakat, Duaa Azmi Abuarqoub, Ismail Sami Mahmoud, Sherine O Obare, Alaa A A Aljabali, Alaaldin M Alkilany, Walhan Alshaer
INTRODUCTION: Doxorubicin (DOX) emerges as a cornerstone in the arsenal of potent chemotherapeutic agents. Yet, the clinical deployment of DOX is tarnished by its proclivity to induce severe cardiotoxic effects, culminating in heart failure and other consequential morbidities. In response, a panoply of strategies has undergone rigorous exploration over recent decades, all aimed at attenuating DOX's cardiotoxic impact. The advent of encapsulating DOX within lipidic or polymeric nanocarriers has yielded a dual triumph, augmenting DOX's therapeutic efficacy while mitigating its deleterious side effects...
April 16, 2024: Expert Opinion on Drug Delivery